Breast Cancer Resistance Protein (Bcrp) Substrates + Capmatinib Interaction
Moderateinteraction on record
Description
Coadministration increased BCRP substrate exposure, which may increase adverse reactions. Decrease substrate dosage if coadministration unavoidable and minimal concentration changes may lead to serious reactions.
Mechanism
TABRECTA inhibits BCRP, increasing substrate exposure
Source: NLP:capmatinib